Clinical Trial Update: Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome [Phase 2]

View source ↗

Summary

Phase 2 proof-of-concept study investigating the efficacy and safety of lulizumab (BMS-931699) or BMS-986142 in Sjögren's syndrome; the trial status is terminat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sjögren Syndrome

Drugs mentioned

• BMS-986142
• lulizumab (BMS-931699)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Sjögren's Syndrome | Phase 2 | Status: TERMINATED | Results posted: 2018-10-04